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ABSTRACT
Pain mechanisms in patients with chronic pancreatitis are
incompletely understood and probably multifactorial.
Recently, evidence from experimental human pain
research has indicated that in many of these patients pain
processing in the central nervous system is abnormal and
mimics that seen in neuropathic pain disorders. The
current review focuses on several lines of evidence
supporting this hypothesis. Hence, the spontaneous and
postprandial pain in chronic pancreatitis may reflect the
characteristic pain features seen in patients with
neuropathic pain. Biochemical and histopathological
findings in tissues from patients with chronic pancreatitis
are similar to those observed in patients with other nerve
fibre lesions. Experimental studies have shown that
patients with chronic pancreatitis show signs of spinal
hyper-excitability counter-balanced by segmental and
descending inhibition. Changes in the brain with cortical
reorganisation to gut stimulation and increased activity in
specific electroencephalographic features characteristic
for neuropathic pain are also seen in patients with chronic
pancreatitis. Finally, principles involved in the treatment of
pancreatic pain have many similarities with those
recommended in neuropathic pain disorders. In conclu-
sion, a mechanism-based understanding of pain in chronic
pancreatitis may have important implications for the
treatment.
One of the most important symptoms in chronic
pancreatitis (CP) is constant or recurrent abdom-
inal pain that is present in 80–90% of patients
during the course of the disease.
1 Pancreatic pain
presents characteristically with severe dull epigas-
tric pain, often radiating directly to the back. The
pain is often recurrent, intense and long-lasting
and may be associated with malnutrition, narcotic
addiction, and major socio-economic problems.
Pain mechanisms are incompletely understood
and probably multifactorial. In some cases the
reason for the pain is obvious, such as extrapan-
creatic (eg, peptic ulcer or bile duct and duodenal
stenosis due to extensive pancreatic fibrosis and
inflammation) or intrapancreatic (eg, pseudocysts)
complications. However, in most patients the
source of the pain remains unknown. In these
cases the following pathophysiological mechan-
isms have been suggested: (1) increased intrapan-
creatic pressure either within the pancreatic duct
or in the parenchyma causing tissue ischaemia;
(2) inflammation in the pancreas; and (3) altera-
tions in pancreatic nerves, including an increase in
nerve fibre diameter and evidence for neurogenic
inflammation.
2–4 Genetic factors probably also play
a role in a patient’s pain experience.
4 Because the
pain mechanisms are poorly understood, treatment
is often empirical and insufficient. Animal models
have contributed to the understanding of pain
pathogenesis in chronic pancreatitis.
5–7 Although
highly relevant to our understanding of pain
mechanisms in general, the data should be inter-
preted cautiously. Hence there are major differ-
ences between pain studies in different species and
strains. Furthermore, mechanisms related to the
relatively short-lasting evoked inflammation in
most animal studies on the one hand and the
long-lasting pain in humans with CP on the
other are probably very different. Recently, evi-
dence from experimental human pain research has
indicated that pain processing in the central
nervous system (CNS) is abnormal and in
many cases may mimic that seen in neuropathic
pain disorders.
8–10 Neuropathic pain is defined as
‘‘pain after a lesion or disease of the afferents in
the peripheral or central nervous system that
normally signals pain’’.
11 Neuropathic pain is
prevalent in all diseases in which lesions of the
nerves are present, and after surgery neuropathic-
like pain can be seen in 20–40% of patients.
12
Although other pain mechanisms may also be of
importance, the following lines of evidence point
towards neuropathic pain mechanisms in patients
with CP:
c Clinical features of the pain
c Biochemical and histological findings
c Spinal changes, with neuronal hyper-excitabil-
ity and amplification of the incoming afferent
activity
c Changes in the brain–gut axis
c Clinical and experimental profile of the drugs
used to treat the pain
Although the characteristics listed above are not
specific for neuropathic pain mechanisms, taken
together they do support this theory. By focussing
on recent neurophysiological experiments in
humans, these topics will be reviewed in the
current paper with the aim of improving our
understanding and treatment of pain in CP.
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FEATURES
Most nerve afferents mediating pain from the
pancreas belong to the splanchnic nerves that pass
through the coeliac ganglion and enter thoracic
dorsal root ganglia. The vagal nerve with cell
bodies in nodose ganglia normally does not
participate in pain signalling but can indirectly
modify spinal pain processing, as shown by in vivo
electrical stimulation.
13 14 Cholinergic modulation
of pancreatic inflammation has also been demon-
strated (for a review, see Fregni et al
15). Hence the
nervous system plays a major role in the inflam-
matory response as well as in pain pathogenesis
and any abnormalities in the sensory system will
invariably affect the disease process.
Neuropathic pain typically presents as a stimu-
lus-independent shooting or burning pain together
with stimulus-dependent increased sensations.
16
The stimulus-independent pain is the result of both
peripheral and central changes (see figs 1 and 2 for
a schematic overview). In the peripheral nervous
system the nerve lesion results in spontaneous
firing of the axons due to the accumulation of
sodium channels and a-adrenoceptors, together
with membrane changes in the primary afferent
neurons. Furthermore, sprouting of sympathetic
axons into the dorsal horn takes place, rendering
the nerves sensitive to autonomic reflexes and
circulating adrenaline, for example, irrespective of
any peripheral input to the nerves. In the spinal
cord, neuroplastic changes and alterations in the
membrane properties result in spontaneous firing
of second-order neurons. These neurons also show
integration of the response to repeated stimulation,
resulting in increased firing (a proxy of the so-
called ‘‘wind-up’’ phenomenon seen in animal
experiments, as described later in this paper).
Normally, the increased afferent barrage of noci-
ceptive information to the brain is counterbalanced
by a ‘‘feed-back’’ inhibitory control system based
on descending nerve pathways originating in the
brain stem. Changes in this feed-back system may
also alter the excitability and result in spontaneous
pain. Central down-regulation of opioid receptors
may also be of importance.
The stimulus-dependent pain is also a result of
the peripheral and central changes. The cardinal
features of classical neuropathic pain in the skin,
such as seen in diabetes and in post-herpetic
neuralgia, are allodynia (a painful response to
stimuli not normally painful) to cold and brush
stimuli and hyperalgesia (increased pain to a
normal painful stimulus) to punctuate stimuli.
16
In the periphery the increased neural activity
results in neurogenic inflammation. The neuro-
transmitters released are typically spread to adja-
cent nerves, rendering them more sensitive. The
central changes are a result of increased nociceptor
drive on second-order neurons leading to central
hyper-excitability and firing at a lower threshold.
Furthermore, there is a phenotypic switch where
Ab fibres (which are normally responsible for non-
painful sensations such as touch) start to release
substance P and calcitonine gene-related peptide
(CGRP). These mediators will stimulate specific
nociceptive receptors in the spinal cord, which
leads to activation of second-order neurons
involved in pain processing. The outcome is
allodynia to touch (brush allodynia). In the spinal
cord, the touch-sensitive Ab fibres normally
terminate in the deeper lamina, whereas neurons
in superficial lamina receive nociceptive informa-
tion mainly from unmyelinated C fibres and thinly
myelinated Ab fibres. In neuropathic pain, how-
ever, the deep Ab fibres sprout to terminate in the
‘‘nociceptive specific’’ lamina 2 and come into
contact with neurons that normally transmit pain,
again resulting in tactile allodynia.
The pain in patients with CP is often burning
and intermittent or shooting, features also seen in
stimulus-independent neuropathic pain.
16 17 In
patients with CP the allodynia due to touch and
movements seen in neuropathic pain from somatic
structures may be reflected during postprandial
pain. After a meal the pancreas may be compressed
from expansion of the stomach and/or affected by
postprandial secretion of pancreatic juice. This
may lead to increased pressure in the pancreatic
tissue, in particular if calculi and/or duct stenosis
are present. The increased pressure and/or shearing
forces will lead to compression of the pancreatic
nerves, and in neurogenic inflammation this results
in stimulus-dependent allodynia and hyperalgesia
via the mechanisms described above. Postprandial
pain may, of course, also result from peptic ulcer
and complications such as stenosis of the duode-
num, and if present these should be treated
appropriately.
BIOCHEMICAL AND HISTOPATHOLOGICAL
FINDINGS
Recent animal studies in which CP has been
induced by intravenous injection of dibutyltin
dichloride or intraductal injection of trinitroben-
zene sulfonic acid have shown behavioural, ser-
ological and histological characteristics similar to
those seen in patients with CP, including damage
of nerve fibres.
561 8 Acute pancreatitis is charac-
terised by intra-acinar activation of proteolytic
enzymes and fusion of zymogen granules with
lysosomal vacuoles containing cathepsin B, con-
tributing to enzyme activation and resulting in
autodigestion of the pancreas.
19 Moreover, enzyme
activation stimulates the release of inflammatory
mediators, which contribute to fat tissue and
haemorrhagic necrosis in the pancreas.
20 Alcoholic
CP, the most common subtype of CP in Western
countries, is the result of recurrent attacks of acute
alcoholic pancreatitis.
21 It has been shown in
alcoholic and autoimmune CP tissue specimens
and in cell culture studies that the profibrotic
cytokines platelet-derived growth factor B and
transforming growth factor b1 are upregulated in
macrophages and ductal cells and stimulate myofi-
broblasts and activated pancreatic stellate cells to
synthesise extracellular matrix.
22–25 These changes
result in the occurrence of inflammation together
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the histological hallmarks of CP.
20 Furthermore, it
was shown 20 years ago
26 that pancreatic pain was
related to inflammation surrounding pancreatic
nerve fibres, indicating a neuropathic component
in this pain. The diameter of intrapancreatic nerve
fibres was increased and the mean area of tissue
served per nerve was decreased, possibly due to
growth and branching of the nerves.
26 Several
neuropeptides, growth factors and corresponding
receptors active in neurogenic inflammation are
upregulated and involved in pain generation in CP.
A detailed description of this topic is far beyond
the scope of this review. (For comprehensive
reviews, the reader is referred to Fasanella et al
4
and Vera-Portocarrero and Westlund.
17) However,
some of the mechanisms causing neurogenic
inflammation in CP will be mentioned and are
illustrated schematically in fig 3.
As shown in fig 3, one of the key receptors in
neurogenic inflammation is the transient receptor
potential vanilloid 1 (TRPV-1). This non-selective
cation channel, preferentially located on sensory
nerve fibres, has been investigated in experimental
pancreatitis in rats,
27 28 in human pancreatic cancer,
and in the normal pancreas.
29 Some inflammatory
mediators, especially those with agonistic effects
on G protein coupled receptors (ie, bradykinin
30
and trypsin
31), are able to indirectly sensitise
TRPV-1 and thereby lower the threshold for
activation in the sensory nerves.
28 Recent data
indicate that hydrogen sulfide-mediated activation
of T-type Ca
2+ channels is also involved in
pancreatitis-related pain.
32 It was shown that
pancreatic hydrogen sulfide targets T-type Ca
2+
channels, which most probably are located on the
peripheral endings of intrapancreatic sensory
nerves. Inhibition of the endogenous hydrogen
sulfide pathway inhibited the pain behaviour in
caerulein-evoked experimental pancreatitis. Inter-
estingly, a similar pro-nociceptive role of hydrogen
sulfide was demonstrated in the mouse colon.
33
The resulting activation of sensory nerves in the
pancreas stimulates the synthesis of substance P
(SP) and CGRP in dorsal root neurons. SP and
CGRP are transported antidromically along the
axon to the site of the lesion, where they stimulate
inflammatory cells to synthesise further amounts
of inflammatory mediators. SP acts primarily via
the neurokinin 1 (NK1) receptor, and in alcoholic
CP it was shown that expression of the NK1
receptor was increased in mononuclear and
Figure 1 No external stimulation (stimulus independent pain). Upper part of figure: A normal C fibre. The fibre is silent,
ie, no noxious information is projected to thalamus when no stimulation is present. Lower part of figure: A diseased
nerve. The diameter of the C fibre is increased. Expression of sodium channels alters the resting potential in the nerve
fibres, rendering them more excitable. a-Adrenoceptors are also expressed and nerve growth factor (NGF) is released.
The activity of descending inhibitory control systems and the amount of opioid receptors in the spinal cord are
decreased. These changes, together, result in stimulus-independent pain, ie, firing of the C fibre, even though no
stimulation is present. 0, no stimulation present/no activity in the nerve fibre; +, stimulation/activity in the nerve fibre;
++, increasing activity in the nerve fibre.
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34 At the
vascular level, the actions of SP are mostly
vasoconstrictive.
17 As the NK1 receptor has also
been detected in the epineural layers of nerves,
where the small arteries feeding the endoneural
vasculature are located,
35 it may also play a direct
role in the generation of pain in CP by causing
vasoconstriction and thereby ischaemia of intra-
pancreactic nerves.
36 SP has been found to directly
stimulate the synthesis of interleukin 8 (IL8) in
macrophages.
37 IL8 also generates hyperalgesia by
stimulation of post-ganglion sympathetic neurons,
and increased expression of IL8 has been detected
in inflammatory cells in alcoholic CP.
37
Figure 2 Response to external stimulation (stimulus dependent pain). (A) A healthy nerve stimulated painfully
(pinprick) and non-painfully (brush). The painful stimulus is projected 1:1 via the C fibre, lamina 1–2 in the dorsal horn,
and the spinothalamic pathways to thalamus and modulated by descending inhibitory control systems. The non-painful
stimulus is projected to the brain through Ab fibres via lamina 5. +, stimulation/activity in the nerve fibre; ++, increasing
activity in the nerve fibre. (B) The diseased C fibre synthesises nerve growth factor (NGF), which affects neighbouring
nerves, resulting in increased sensation. The diameter of the diseased nerve fibres increases, the fibres express
increasing numbers of sodium channels and a-adrenoceptors. The activity of descending inhibitory control systems and
the number of opioid receptors decrease, and the stimulus is amplified. Ab fibres respond to NGF by increasing their
sensitivity and sprout into lamina 2, establishing direct synaptic contact with the spinothalamic projection neuron. This
results in allodynia to touch. These changes, all together, result in increased response to stimulation.
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generation in CP was further provided by the
finding that growth associated protein 43 is
increased in pancreatic nerve fibres in alcoholic
CP.
38 This protein was shown to be re-expressed
after neuronal lesions,
39 introducing it as a marker
of neuronal growth and plasticity. Moreover, the
neurotrophin nerve growth factor and its high
affinity receptor tyrosin kinase receptor A are
upregulated in alcoholic CP.
40 Nerve growth factor
is possibly a regulator of the synthesis of SP and
CGRP
41 and modulates nociception in peripheral
nerve fibres.
42 Another neurotrophin with impact
on neuropathic pain in CP is brain-derived neuro-
trophic factor, which is increased in ductular
complexes, degenerating acinar cells, and enlarged
nerve fibres as well as in intrapancreatic ganglia in
CP.
43 During peripheral inflammation, brain-
derived neurotrophic factor is upregulated in dorsal
root ganglia in rats.
44 Recent studies have also
identified artemin
45 and the cannabinoid system
46
as possible mediators of neural changes and pain
perception in CP. Artemin belongs to the family of
glial-derived neurotrophic factors and enhances
survival, proliferation and regeneration of neurons.
Both artemin and its receptor are increased in CP
tissue.
45 Moreover, the expression of the cannabi-
noid receptor 1 is upregulated in human acute
pancreatitis, a finding that is accompanied by an
increase in the endocannabinoid anandamide.
46 In
another study, cannabinoid receptors located on
peripheral nociceptive endings have been shown to
negatively modulate nociceptors and inhibit release
of neuropeptides.
47
These findings point towards a complex inter-
play of inflammatory cells, nerve fibres, neuropep-
tides, and corresponding receptors, resulting in the
phenomenon of peripheral (and subsequent cen-
tral) sensitisation of the nervous system.
SPINAL CHANGES WITH HYPER-EXCITABILITY
AND AMPLIFICATION OF THE INCOMING NEURAL
ACTIVITY
In most diseases characterised by chronic pain,
sensitisation of the nervous system is a cardinal
feature. This is also the case in neuropathic pain
disorders. This sensitisation results in plastic
changes in the neurons at spinal (and supraspinal)
sites. It has been proposed that these plastic
changes in the dorsal horn of the spinal cord
correspond to the mechanism in ‘‘long-term
potentiation’’.
48 Through a cascade of molecular
changes at the cell synapses, long-term potentia-
tion results in an increase in synaptic transmission
efficacy, thus leading to an increase in synaptic
strengthening which further increases electrical
activity and sensory information transmission.
This sensitisation may ultimately result in an
autonomous state in which the central nervous
system reports pain even in the absence of
peripheral noxious input.
49 Sensitisation includes
both peripheral and central components. Peripheral
nociceptor sensitisation underlies the hyperalgesia
that develops immediately at the site of injury.
However, in CP, acute inflammation of the gland
has normally ceased, and central rather than
peripheral sensitisation is thought to account for
most of the symptoms experienced by the patients.
In animal studies, central sensitisation is charac-
terised by increased spontaneous activity,
decreased firing threshold, and expansion of the
receptive fields of dorsal horn neurons.
50 51 The
increase in excitability of spinal cord nociceptive
neurons amplifies the signal coming from the
periphery, resulting in allodynia and hyperalgesia.
The alterations in functional structure may result
in central plasticity and ‘‘pain memory,’’ which
after some time may be consolidated and indepen-
dent of the original peripheral input.
50 51 Human
experimental models have been used to sensitise
the gut and mimic the findings in animal studies.
52
Studies using electrical and mechanical stimuli
have indicated that acid perfusion of the oesopha-
gus results in peripheral as well as central
sensitisation of the nervous system.
53 54 In condi-
tions with chronic pain there is substantial
evidence for persistent central changes that outlive
the initial disease. Hence, when the peripheral
stimulation (such as inflammation due to CP) has
subsided, sensitised second-order neurons continue
to fire, and sub-threshold regulatory stimuli are
still perceived as painful.
Importantly, CP is often complicated by dia-
betes, and it is estimated that 60–70% of patients
with diabetes suffer from mild to severe forms of
nervous system damage including autonomic
neuropathy.
55 Using a multimodal experimental
approach, Frøkjær et al
56 recently demonstrated
that gastrointestinal sensory nerves in patients
with diabetes are affected throughout all layers of
the gut. The neuronal damage will invariably result
in changes in the neuronal pain matrix, including
interactions between peripheral and central pain
mechanisms, and thereby the sensory processing in
CP. Moreover, activation of pain related structures
in the brain might trigger behavioural responses
resulting in negative changes in eating, daily
activity and sleep patterns that could worsen the
pain.
15 57
Although simplified, referred pain is a result of
visceral and somatic fibres converging on the same
second-order neuron (for details see Arendt-Nielsen
et al
58). Hence spinal hyper-excitability will be
Summary box 1
c Constant and/or recurrent abdominal pain is present in 80–90% of patients
with chronic pancreatitis
c The spontaneous and postprandial pain in chronic pancreatitis may reflect the
characteristic stimulus independent and stimulus dependent pain features
seen in patients with neuropathic pain
c Biochemical an histopathological features in tissues from patients with
chronic pancreatitis mimic those observed in tissues from patients with other
nerve fibre lesions
c The principles involved in the treatment of pancreatic pain have many
similarities with those used in neuropathic pain disorders
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localisation and sensitivity of the referred pain
area.
59 In patients with CP, Buscher et al
60
investigated the sensitivity in the referred pain
areas of the abdomen. Although findings were not
completely consistent between genders, they
showed increased sensation to pressure (predomi-
nantly a deep muscle stimulus). On the other
hand, there were higher thresholds to electrical
skin stimulation in dermatome T10, the ‘‘viscer-
otome’’ that shares innervation with the pancrea-
tic nerves, whereas the sensation in other
dermatomes (C5, T4, L1 and L4) was normal.
The authors suggested that this local hyposensi-
tivity was related to segmental inhibition caused
by a local feedback system in the spinal cord. As
with the deep stimulus, changed sensation in the
somatic referred pain area (sharing central termi-
nation with activated visceral nerves) has also been
shown experimentally in healthy subjects as well
as in patients with diseases such as appendicitis
and choledocholithiasis.
61 62 Therefore, such data
give evidence for central hyper-excitability in CP.
In experimental studies the pancreas is difficult
to access and there are potentially harmful
complications during endoscopic procedures.
Therefore it has not yet been possible in humans
to investigate directly whether allodynia or other
characteristic features of neuropathic pain are
present during manipulation of the pancreas.
However, visceral pain is typically diffuse and
difficult to localise, which to a large extent can be
explained by the widespread termination of visc-
eral afferents into second-order neurons in multiple
segments of the spinal cord.
63 Due to this overlap in
central termination of visceral afferents, disease
mechanisms affecting the pancreas are typically
also activated during pain stimulation of nearby
organs like the duodenum and oesophagus.
64
Dimcevski et al
91 0showed that the referred pain
area to experimental electrical stimulation of the
oesophagus in CP was increased compared with
that in healthy controls (fig 4). Because increases in
the size of the referred pain area after experimental
stimulation have also been shown in other patient
groups with organic diseases (eg, erosive and non-
erosive oesophagitis, peptic ulcer disease) this
strengthens the validity of the findings.
65 66
Changes in the referred pain area, however, are
not specific for any specific pain disorder, but
merely reflect the importance of central changes
such as seen those in neuropathic pain.
Another feature that is predominant in central
sensitisation is wind-up (in humans this is termed
temporal summation or central integration).
Temporal summation is a frequency dependent,
gradual response of ‘‘wide-dynamic’’ spinal neu-
rons to repetitive stimuli, which may lead to
increased excitability if the stimulus is sufficiently
strong.
67 68 Hence, afferent fibres that are repeat-
edly stimulated give a progressive increase in
second-order neuronal responsiveness. Dimcevski
et al found an increase of temporal summation in
the skin,
64 muscle and oesophagus
10 in patients
with CP (fig 4). Although not specific for any pain
disorder, facilitated temporal summation is pre-
valent in neuropathic pain patients,
69–73 and thus
these findings support the important role of
neuropathic pain mechanisms in CP.
The dissociation between local sensory distur-
bances in the area of nerve damage and sponta-
neous pain per se suggests that the pain is
neuropathic in nature. However, other mechan-
isms are also of importance. The second-order
neurons in the spinal cord are subject to descending
control from higher brain centres.
74–77 One of the
first systems described was diffuse noxious inhibi-
tory control (DNIC), defined as ‘‘painful hetero-
topic stimuli that can cause suppression of
nociceptive activity in dorsal horn neurons’’.
DNIC was shown to involve a spinal–suprasp-
inal–spinal feedback loop producing a descending
inhibitory control.
78 Apart from being inhibitory,
descending pain control from the brainstem can
also be facilitating, and the balance between the
inhibiting and activating systems may determine
the overall level of excitability (and hence pain) of
the neuron network in the dorsal horn.
79 80 In an
animal model of persistent pancreatic pain Vera-
Portocarrero et al
81 reported that descending facil-
itation from the rostral ventromedial medulla plays
a critical role in the maintenance of pancreatic
pain. When they selectively destroyed cells in this
brain centre, it attenuated pancreatic-induced
hypersensitivity. Several cortical centres are con-
nected to the periaquaductal grey and the raphe
magnus nucleus in the medulla, which again exert
control over the spinal cord. The balance between
the excitatory system and the inhibitory modula-
tion is therefore a major determinant for the final
interpretation of the pain, and descending influ-
ence from brainstem structures seems to be the
major way by which the brain controls pain
perception.
75 76 82–84 Recent evidence supports the
notion that in patients with functional pain
disorders, such as irritable bowel syndrome, the
inhibitory control system functions insufficiently.
This may result in an increased barrage of noxious
stimulation reaching pain centres in the brain.
85 On
the other hand, in patients with organic disorders
the descending control system is probably fully
activated to prevent hyperalgesia evoked by the
afferent activity arising in the diseased tissue.
Hence, hypoalgesia to experimental visceral stimu-
lation was seen in patients with diseases such as
oesophagitis, Crohn’s disease and peptic
ulcers.
65 86 87 Therefore in patients with CP there
will probably be an activation of the descending
inhibitory system, whereby the pain system tries
to counterbalance the incoming nociceptive infor-
mation from the pancreas. However, activation of
descending control systems probably affects the
spinal cord diffusely, resulting in widespread
hypoalgesia to stimulation from other body
regions. Correspondingly, in an experimental study
in which the skin, oesophagus and duodenum were
stimulated, generalised hypoalgesia was found in
Recent advances in basic science
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controls (see fig 5).
Evidence indicating increased descending inhibi-
tion in CP was also seen in a study based on evoked
brain potentials resulting from painful stimulation
of the oesophagus. Evoked brain potentials are the
summated outcome of a series of time-locked
electroencephalographic (EEG) responses to exter-
nal stimuli.
88 89 Reduction in latency of the evoked
brain potentials may be related to hyper-excit-
ability within central pain pathways evoked by the
chronic pain attacks in the patients.
90 This is most
probably due to central hyper-excitability and
opening of faster conducting latent connections.
Correspondingly, in patients with CP the latency
to upper gut stimulations was decreased.
9
However, the latency to sigmoid stimulations
was decreased (Drewes et al, unpublished data)
(fig 5). The reason for these findings is probably
that, although the pain in CP evokes hyper-
excitability in a widespread area of the spinal cord,
this is predominant in the thoracic region. Hence
the excitability in remote lumbar segments receiv-
ing afferents from the sigmoid colon could be
dampened by the descending control systems
exerting diffuse inhibition of the incoming activity
at all segmental levels of the spinal cord. However,
electrical stimulation may activate both vagal and
splanchnic pathways.
91 Because activation of the
splanchnic/spinal pathways probably activates an
endogenous pain inhibitory pathway, whereas
vagal stimulation may result in facilitation, this
can make interpretation of the data difficult.
13
The most recent neurophysiological evidence for
neuropathic pain mechanisms in CP is based on
studies of the brain. Several experimental and
clinical studies indicate that deafferentation,
chronic pain, and hyperalgesia are associated with
functional reorganisation of the cortex. In parti-
cular, there is evidence for neuroplastic changes
and reorganisation of the brain in patients with
amputations and neuropathic pain.
92 Importantly,
the degree of cortical reorganisation correlates with
the subjective pain rating, and the cortical changes
can be reversed by analgesic interventions (for a
review, see Wiech et al
93). In recent experiments
carried out by our group, analysis of the brain
sources to upper gut stimulation showed that the
Figure 3 Schematic illustration of some of the neuropeptides and receptors that play a role in neurogenic inflammation
in chronic pancreatitis. Damage to acinar cells results in upregulation of proinflammatory cytokines, trypsin and
bradykinin. These molecules, together with protons, hydrogen sulfide, serotonin and calcium, lower the threshold for
activation of peripheral sensory nerve fibres, in part mediated by the ion channel transient receptor potential vanilloid 1
(TRPV-1). As a consequence, dorsal root neurons synthesise substance P (SP) and calcitonin gene-related peptide
(CGRP). These peptides reach the inflamed tissue antidromically and contribute further to inflammation and pain. For
more detailed information, see text. B2-R, bradykinin B2 receptor; BDNF, brain-derived neurotrophic factor;
GAP-43, growth-associated protein 43; GFR-a3, glial derived neurotrophic factor (GDNF) family receptor a3;
5-HT, serotonin; IL, interleukin; NGF, nerve growth factor; NK1-R, neurokinin 1 receptor; PAR-2, proteinase activated
receptor 2; PG, prostaglandin; TNF, tumour necrosis factor; TrkA and B, tyrosin kinase receptor A and B.
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9 The
insula plays an important role in the integration of
the visceral sensory and motor activity together
with the limbic system. It is connected to many
limbic structures as well as to the motor cortex and
basal ganglia. Thus the changes in the insula region
in patients with CP may reflect severe disturbances
in the coordination and sensory processing of
visceral pain. There were also more discrete
changes in the cingulate cortex where the neuronal
source was more posterior in the patients. The
findings indicate that pain in chronic pancreatitis
leads to changes in cortical projections of the
nociceptive system, supporting a neuropathic
component in pancreatic pain.
Finally, is has been proposed that changes of
power in the theta (3.5–7.5 Hz) EEG band may be
a hallmark of patients with different kinds of
neuropathic pain.
94–96 Recently, Sarnthein and co-
workers showed that patients with neuropathic
pain disorders exhibited higher spectral power of
the resting EEG especially in the theta range,
97
which normalised after successful treatment. It
was hypothesised that the theta activity reflects a
disturbance in higher cognitive functions such as
those engaged in neuropathic pain. In a recent
study we examined the EEG during painful
stimulation of the oesophagus in patients with
CP.
98 In comparison with controls, there was
increased activity in the theta band in CP patients,
and such findings also support the neurogenic pain
hypothesis.
Interestingly, Fregni and co-workers
15 recently
proposed that the cortical neural network activated
by pancreatic inflammation may act via a feed-
back mechanism and modulate the immune
system, thereby influencing the healing process
and decreasing (or increasing) pancreatic inflam-
mation. The neuroplastic changes may become
self-perpetuating, and account for the disabling
chronic pain. The authors proposed that the cyclic
variation of pain levels and flare-ups may not only
be a simple response to inflammation but, on the
contrary, could reflect CNS modulation of the
inflammatory process. Non-invasive brain stimula-
tion can enhance or suppress activity in the
targeted regions, and repetitive transcranial mag-
netic stimulation has been effective in modifying
the dysfunctional brain activity associated with
pain. In a pilot study, Fregni et al demonstrated
increased activity in the secondary somatosensory
cortex (located close to the insula) in patients with
CP. Magnetic stimulation, which suppresses the
activity in the targeted brain region, resulted in
relief of the visceral pain.
15 Although these observa-
tions need to be replicated in larger studies, they
Figure 4 The visceral afferents (black) terminate diffusely into second-order neurons at multiple segments in the spinal
cord. Thus, pancreatic diseases will result in widespread central hyper-excitability of the second-order neurons. This
may also affect the response to stimulation of nearby organs like the oesophagus and the duodenum with afferents
terminating in the same segments. Due to sensitisation, the neurons widen their receptive fields, and the increased size
of the referred pain area seen in these patients may be explained by convergence of somatic nerves (grey and white) in
the same area. Insert: In these conditions, a frequency dependent repeated stimulus (eg, from 0.1 to 0.3 Hz) leads to
central integration of the response (black lines) and increased sensibility, as recorded on the visual analogue scale
(VAS).
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PROFILE OF DRUGS USED TO TREAT THE PAIN IN
CHRONIC PANCREATITIS
Treatment of CP depends on the clinical course
and abnormal imaging findings (for reviews, see
Mitchell et al
99 and Steer et al
100). Thus, pseudocysts
and ductal obstruction may lead to endoscopic,
extracorporeal shock-wave lithotripsy and/or sur-
gical treatment, whereas resection of a dominant
inflammatory mass (typically in the pancreatic
head) may relieve the patient of the pain. It is of
utmost importance to exclude autoimmune pan-
creatitis if an inflammatory mass is present
because this relatively new entity of chronic
pancreatitis responds to steroid treatment.
101
Neurolysis and nerve blocks have mainly been
used in the past, whereas methods based on
endoscopic ultrasound and thoracoscopic splanch-
nicectomy are now increasingly used. Alternative
treatments have included transcutaneous electrical
nerve stimulation, spinal cord stimulation, and
transcraniel magnetic stimulation.
41 5However, in
most patients medical treatment is the mainstay of
pain management (for reviews, see Andren-
Sandberg et al
1 and van Esch et al
49). Treatment
of the pain in chronic pancreatitis is difficult, and
although the World Health Organization analgesic
ladder recommends starting with non-narcotic
analgesics followed by weak narcotics (with or
without non-opioids and adjuvant therapies), it is
often necessary to use strong opioids.
14 9 The
cornerstone in the treatment of neuropathic pain
relies on multifunctional drugs, targeting different
areas in the CNS, such as tricyclic antidepressants,
gabapentin/pregabalin, tramadol and, eventually,
opioids (for a review, see Finnerup et al
102). Drugs
shown to be effective in neuropathic pain also
seem to be efficient in CP. Tricyclic antidepressants
and pregabalin, which are recommended in
neuropathic pain, have in our experience been of
value as adjuvant therapy in difficult patients.
Interestingly, gabapentin was shown to potentiate
the effect of morphine in an animal model of
pancreatitis.
103 In animals, opioids have been
shown to influence the nociceptive processing in
experimental pancreatitis.
6 Although narcotics
have many side effects and carry a risk of addiction,
several papers report that opioids are among the
Figure 5 Visceral and somatic hypoalgesia found in the oesophagus and duodenum in chronic pancreatitis patients
can be explained by activation of the descending inhibitory control systems located in the brainstem (opaque large
arrow). These systems are normally active during painful stimuli and counterbalance the noxious activity, resulting in a
dampening of the neuronal activity. This effect is diffusely distributed throughout the spinal cord, and when it is strongly
activated it can result in hyposensitivity to stimulation of other organs and somatic structures. A schematic, although
simplified explanation, is shown by the latencies of the early components of evoked brain potentials to electrical gut
stimulation in patients (black) and controls (grey). As the electrical stimulation bypasses the peripheral receptors, the
latency of the early components (the first negative component, N1, indicated by arrows) represents the sensitivity of
central neurons. After stimulation of the upper gut, the neuronal hyper-excitability caused by the pancreatic pain results
in reduced latency of N1. However, in the spinal segments receiving nerve afferents from the sigmoid colon – where the
pancreatic pain probably does not result in neuronal hyper-excitability – the activation of the descending inhibition
results in prolonged latency of N1.
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pain (for a review, see Cruccu
104). Wilder-Smith et
al
105 demonstrated that tramadol, a weak opioid
drug with several non-opioid effects in the central
nervous system, in high doses was superior to
traditional opioids in the treatment of pain in
CP. Among the strong opioids, oxycodone has
shown to be effective in neuropathic pain.
106
Correspondingly, in an experimental study,
Staahl and co-workers
8 administered oxycodone
and morphine in equipotent dosages to patients
with pain due to CP. They showed that oxycodone
was superior to morphine in attenuating pain
evoked from somatic structures (skin and muscle)
as well as from the oesophagus. The superior effect
of oxycodone on pain from somatic structures was
not seen in a similar study in healthy subjects,
107
and probably the disease process in CP was
responsible for this difference. Hence oxycodone,
although a strong m-agonist, also has some effects
on the k-opioid receptor. Animal experiments have
shown both a peripheral and a spinal upregulation
of the k-opioid receptors in the presence of
inflammation.
108 This upregulation will affect the
pain system in several tissues, as has been shown in
the CP patients.
109 The potential effect of a
receptor differentiated effect was supported in a
clinical study involving a peripherally restricted k
agonist (ADL 01-0101). This agonist showed
analgesic effects in patients with pain due to
CP.
110 Hence in contrast to a pure m-agonist such as
morphine, opioids with more complex effects such
as tramadol and oxycodone may be of value in CP.
Experimental studies should, however, be sup-
ported by large-scale clinical studies.
CONCLUSION
The pathogenesis of pain in CP is poorly under-
stood. In a subset of patients, extrapancreatic
diseases such as peptic ulcer and intrapancreatic
complications such as duct obstruction or pseudo-
cysts can explain the pain and should be treated
appropriately. Endoscopic or surgical treatments
are still the mainstay in selected cases if an
inflammatory mass is present or there is substantial
evidenceforincreasedpressureinthepancreaticduct
or gland.
111–113 When an inflammatory mass is
present,autoimmunepancreatitisandinflammatory
pseudotumor have to be considered.
114 However, in
the majority of patients the cause of the pain is not
obvious. Although the different lines of ‘‘evidence’’
presented in the current paper are not specific for
neuropathic pain, they point towards this mechan-
ism as a major explanation for the painseenin many
patients. If neuropathic pain dominates the clinical
picture, surgical procedures may increase the neuro-
nal lesions and worsen the pain. Furthermore,
pharmacological treatment of neuropathic pain
differs from that of other pain disorders, with focus
on multifunctional drugs having different effects on
the CNS, such as tricyclic antidepressants, tramadol
and ion-channel inhibitors. Future studies should
therefore aim at developing methods to characterise
neuropathy in individual patients before they are
subjected to treatment, and at addressing the
prevalence of neuropathic pain in a large series of
CP patients. Furthermore, the effect of drugs
effective against neuropathy should also be evalu-
ated systematically in well defined patient cohorts.
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